Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
3 Stocks You Can Buy and Hold for Decades
05:57am, Saturday, 02'nd Jul 2022
These companies are built to last.
2 Biotech Stocks That Could Soar in the Third Quarter
05:41am, Saturday, 02'nd Jul 2022
Bristol Myers Squibb and Bluebird Bio have drugs in their pipelines that could soon earn FDA approval.
5 S&P 500 Stocks Ready to Break Out
11:50am, Wednesday, 29'th Jun 2022
Although Wall Street is hurting right now, not all S&P 500 stocks are getting thrashed. And these beauties are getting ready to break out.
Here's one sector that offers ‘offense, defense, growth and value'
07:15pm, Tuesday, 28'th Jun 2022
Healthcare is the one sector that has everything an investor needs to navigate the market uncertainty, says Virtus Investment Partners' Joe Terranova. “XLV” is down nearly 10% year-to-date.
Bristol-Myers Is Melting-Up Again
06:46pm, Tuesday, 28'th Jun 2022
Late last year, BMY broke out of a long-term range, and that break out is continuing. BMY stalled for the last few months, but its recent strong activity indicates a probable return to outperforming t
Investors Need Not Be Alarmed by Drug Patent Expirations
04:02pm, Tuesday, 28'th Jun 2022
Investors who are sweating the loss of patent protection for some of Big Pharma's top-selling drugs should relax.
Bristol-Myers Squibb: Annual Mid Single-Digit Growth Equals Incremental Upside
12:17pm, Tuesday, 28'th Jun 2022
BMY shares were stagnant for nearly 5 years before gaining ~30% across the past 6 months. Celgene acquisition added $15bn per annum to top line, but more importantly, a pipeline of approvable assets.
All-time highs for pharma stocks: Names to trade now
06:59pm, Monday, 27'th Jun 2022
Big pharma surges, and here are the names to trade. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Dan Nathan, Courtney Garcia and Karen Finerman.
Bristol Myers (BMY) Breyanzi Gets FDA Nod for Label Expansion
02:36pm, Monday, 27'th Jun 2022
Bristol Myers' CAR T cell therapy Breyanzi was approved by the FDA for relapsed or refractory large B-cell Lymphoma after one prior therapy.
Final Trades: CHPT, BMY, WMT & XBI
08:13pm, Friday, 24'th Jun 2022
The final trades of the week. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Steve Grasso, Guy Adami and Pete Najarian.
Bristol Myers must face $6.4 billion lawsuit over delayed cancer drug
02:52pm, Friday, 24'th Jun 2022
A U.S. judge on Friday refused to dismiss a $6.4 billion lawsuit accusing Bristol Myers Squibb Co of delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp, whi
3 Dirt Cheap Dividend Stocks to Buy Hand Over Fist
11:15am, Thursday, 23'rd Jun 2022
These stocks offer dividend yields ranging from 2% to an astronomical 7.1%.
Bristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs 43rd Annual Global Healthcare Conference
03:52pm, Wednesday, 15'th Jun 2022
Bristol-Myers Squibb Company (NYSE:BMY ) Goldman Sachs 43rd Annual Global Healthcare Conference June 15, 2022 12:20 PM ET CorporateParticipants Adam Lenkowsky - Senior Vice President and General Manag
7 Blue-Chip Stocks With Strong Dividend Yields
07:15pm, Thursday, 09'th Jun 2022
Blue-Chip stocks are particularly attractive in volatile times like now. These picks include a strong dividend as well.
Bristol Myers (BMY) to Acquire Turning Point, Withdraws sBLA
03:03pm, Monday, 06'th Jun 2022
Bristol Myers (BMY) is set to acquire Turning Point to bolster its oncology portfolio. The company also withdraws its sbLA for Reblozyl.
